Home
/
ANI PHARMACEUTICALS INC
/
Financials
/
Quarterly
ANI PHARMACEUTICALS INC — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that ANI PHARMACEUTICALS INC filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2020
Mar 31, 2020
$49.77M
May 7, 2020
Q3
2019
Sep 30, 2019
$51.34M
Nov 6, 2019
Q2
2019
Jun 30, 2019
$54.36M
Aug 7, 2019
Q1
2020
Mar 31, 2019
$52.89M
May 7, 2020
Q3
2019
Sep 30, 2018
$50.70M
Nov 6, 2019
Q2
2019
Jun 30, 2018
$47.27M
Aug 7, 2019
Q1
2019
Mar 31, 2018
$46.48M
May 9, 2019
Q3
2018
Sep 30, 2017
$48.16M
Nov 6, 2018
Q2
2017
Jun 30, 2017
$44.76M
Aug 3, 2017
Q1
2018
Mar 31, 2017
$36.63M
May 8, 2018
Q3
2017
Sep 30, 2016
$38.53M
Nov 2, 2017
Q2
2017
Jun 30, 2016
$31.34M
Aug 3, 2017
Q1
2017
Mar 31, 2016
$20.56M
May 4, 2017
Q3
2016
Sep 30, 2015
$19.97M
Nov 3, 2016
Q2
2016
Jun 30, 2015
$19.52M
Aug 4, 2016
Q1
2016
Mar 31, 2015
$18.80M
May 5, 2016
Q3
2015
Sep 30, 2014
$17.39M
Nov 3, 2015
Q2
2015
Jun 30, 2014
$6.65M
Aug 4, 2015
Q1
2015
Mar 31, 2014
$10.90M
May 5, 2015
Q3
2014
Sep 30, 2013
$7.84M
Nov 10, 2014
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$227.81M
Nov 7, 2025
Q2
2025
Jun 30, 2025
$211.37M
Aug 8, 2025
Q1
2025
Mar 31, 2025
$197.12M
May 9, 2025
Q3
2025
Sep 30, 2024
$148.33M
Nov 7, 2025
Q2
2025
Jun 30, 2024
$138.04M
Aug 8, 2025
Q1
2025
Mar 31, 2024
$137.43M
May 9, 2025
Q3
2024
Sep 30, 2023
$131.83M
Nov 8, 2024
Q2
2024
Jun 30, 2023
$116.55M
Aug 6, 2024
Q1
2024
Mar 31, 2023
$106.79M
May 10, 2024
Q3
2023
Sep 30, 2022
$83.82M
Nov 8, 2023
Q2
2023
Jun 30, 2022
$73.86M
Aug 9, 2023
Q1
2023
Mar 31, 2022
$64.48M
May 8, 2023
Q3
2022
Sep 30, 2021
$52.06M
Nov 9, 2022
Q2
2022
Jun 30, 2021
$48.63M
Aug 8, 2022
Q1
2022
Mar 31, 2021
$54.52M
May 10, 2022
Q3
2021
Sep 30, 2020
$52.98M
Nov 1, 2021
Q2
2021
Jun 30, 2020
$48.47M
Aug 6, 2021
Q1
2021
Mar 31, 2020
$49.77M
May 7, 2021
Q3
2020
Sep 30, 2019
$51.34M
Nov 5, 2020
Q2
2020
Jun 30, 2019
$54.36M
Aug 6, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$26.62M
Nov 7, 2025
Q2
2025
Jun 30, 2025
$8.55M
Aug 8, 2025
Q1
2025
Mar 31, 2025
$15.68M
May 9, 2025
Q3
2025
Sep 30, 2024
($24.17M)
Nov 7, 2025
Q2
2025
Jun 30, 2024
($2.29M)
Aug 8, 2025
Q1
2025
Mar 31, 2024
$18.21M
May 9, 2025
Q3
2024
Sep 30, 2023
$9.94M
Nov 8, 2024
Q2
2024
Jun 30, 2023
$6.25M
Aug 6, 2024
Q1
2024
Mar 31, 2023
$1.44M
May 10, 2024
Q3
2023
Sep 30, 2022
($8.60M)
Nov 8, 2023
Q2
2023
Jun 30, 2022
($14.92M)
Aug 9, 2023
Q1
2023
Mar 31, 2022
($20.13M)
May 8, 2023
Q3
2022
Sep 30, 2021
($4.45M)
Nov 9, 2022
Q2
2022
Jun 30, 2021
($14.11M)
Aug 8, 2022
Q1
2022
Mar 31, 2021
$86.0K
May 10, 2022
Q3
2021
Sep 30, 2020
$434.0K
Nov 1, 2021
Q2
2021
Jun 30, 2020
($12.34M)
Aug 6, 2021
Q1
2021
Mar 31, 2020
($7.01M)
May 7, 2021
Q3
2020
Sep 30, 2019
$3.90M
Nov 5, 2020
Q2
2020
Jun 30, 2019
$6.59M
Aug 6, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$36.24M
Nov 7, 2025
Q2
2025
Jun 30, 2025
$13.89M
Aug 8, 2025
Q1
2025
Mar 31, 2025
$26.19M
May 9, 2025
Q3
2025
Sep 30, 2024
($20.52M)
Nov 7, 2025
Q2
2025
Jun 30, 2024
$5.17M
Aug 8, 2025
Q1
2025
Mar 31, 2024
$20.31M
May 9, 2025
Q3
2024
Sep 30, 2023
$17.95M
Nov 8, 2024
Q2
2024
Jun 30, 2023
$12.40M
Aug 6, 2024
Q1
2024
Mar 31, 2023
$9.90M
May 10, 2024
Q3
2023
Sep 30, 2022
($5.00M)
Nov 8, 2023
Q2
2023
Jun 30, 2022
($12.91M)
Aug 9, 2023
Q1
2023
Mar 31, 2022
($19.20M)
May 8, 2023
Q3
2022
Sep 30, 2021
($3.56M)
Nov 9, 2022
Q2
2022
Jun 30, 2021
($15.55M)
Aug 8, 2022
Q1
2022
Mar 31, 2021
$3.05M
May 10, 2022
Q3
2021
Sep 30, 2020
$2.80M
Nov 1, 2021
Q2
2021
Jun 30, 2020
($11.31M)
Aug 6, 2021
Q1
2021
Mar 31, 2020
($7.84M)
May 7, 2021
Q3
2020
Sep 30, 2019
$7.33M
Nov 5, 2020
Q2
2020
Jun 30, 2019
$9.29M
Aug 6, 2020